These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16236428)

  • 21. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
    Wesierska-Gadek J; Kramer MP; Maurer M
    Food Chem Toxicol; 2008 Apr; 46(4):1327-33. PubMed ID: 17933449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A step toward optimization of cancer therapeutics. Physiologically based modeling of circadian control on cell proliferation.
    Clairambault J
    IEEE Eng Med Biol Mag; 2008; 27(1):20-4. PubMed ID: 18270046
    [No Abstract]   [Full Text] [Related]  

  • 23. Synthesis and biological evaluation of guanidino analogues of roscovitine.
    Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
    Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
    N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
    Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
    Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
    Dou QP; Smith DM; Daniel KG; Kazi A
    Prog Cell Cycle Res; 2003; 5():441-6. PubMed ID: 14593738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell cycle dependent response and combined treatment of tumor.
    Terasima T; Ohara H; Miyamoto T; Watanabe M; Takabe Y; Watanabe I
    Jpn J Antibiot; 1977 Dec; 30 Suppl():49-56. PubMed ID: 77340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
    Coley HM; Shotton CF; Kokkinos MI; Thomas H
    Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents.
    Ribba B; Saut O; Colin T; Bresch D; Grenier E; Boissel JP
    J Theor Biol; 2006 Dec; 243(4):532-41. PubMed ID: 16930628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
    Collins I; Garrett MD
    Curr Opin Pharmacol; 2005 Aug; 5(4):366-73. PubMed ID: 15964238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel synthetic oleanolic acid derivative with amino acid conjugate suppresses tumour growth by inducing cell cycle arrest.
    Lu XM; Yi HW; Xu JL; Sun Y; Li JX; Cao SX; Xu Q
    J Pharm Pharmacol; 2007 Aug; 59(8):1087-93. PubMed ID: 17725850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin-dependent kinases as targets for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Polo-like kinase in cancer therapy.
    Degenhardt Y; Lampkin T
    Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delay equations modeling the effects of phase-specific drugs and immunotherapy on proliferating tumor cells.
    Barbarossa MV; Kuttler C; Zinsl J
    Math Biosci Eng; 2012 Apr; 9(2):241-57. PubMed ID: 22901063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling cell population growth with applications to cancer therapy in human tumour cell lines.
    Basse B; Baguley BC; Marshall ES; Wake GC; Wall DJ
    Prog Biophys Mol Biol; 2004; 85(2-3):353-68. PubMed ID: 15142752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
    Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
    Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive relevance for clinical outcome of in vitro sensitivity evaluated through antimetabolic assay.
    Silvestrini R; Sanfilippo O; Daidone MG; Zaffaroni N
    Recent Results Cancer Res; 1984; 94():140-50. PubMed ID: 6494575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.